X4 PHARMACEUTICALS, INC Fair Value Adjustment of Warrants
X4 PHARMACEUTICALS, INC (XFOR) reported Fair Value Adjustment of Warrants of -$4.60 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2024-11-13
- X4 PHARMACEUTICALS, INC fair value adjustment of warrants for the quarter ending 2024-09-30 was $1.86M.
- X4 PHARMACEUTICALS, INC fair value adjustment of warrants for the quarter ending 2024-06-30 was -$20.21M, a 167.70% decline year-over-year.
- X4 PHARMACEUTICALS, INC fair value adjustment of warrants for the quarter ending 2024-03-31 was $13.76M.
- X4 PHARMACEUTICALS, INC fair value adjustment of warrants for the quarter ending 2023-09-30 was -$25.16M.
- X4 PHARMACEUTICALS, INC fair value adjustment of warrants for fiscal 2021 was $0.00.
- X4 PHARMACEUTICALS, INC fair value adjustment of warrants for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- X4 PHARMACEUTICALS, INC fair value adjustment of warrants for fiscal 2019 was $288.00K, a 91.52% decline from fiscal 2018.
- X4 PHARMACEUTICALS, INC fair value adjustment of warrants for fiscal 2018 was $3.40M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 12 month as first filed |
|---|---|---|---|---|---|
| 2024-09-30 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$18.35M derived: sum of 2 quarters · filed 2024-11-13 | -$4.60M 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | -$20.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$6.46M 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $13.76M 10-Q · filed 2024-05-07 | ||||
| 2023-09-30 | -$25.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $4.70M derived: sum of 2 quarters · filed 2024-11-13 | -$743.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $29.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $24.42M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$5.44M 10-Q · filed 2024-05-07 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | ||||
| 2021-12-31 | $0.00 10-K · filed 2022-03-17 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2022-03-17 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-04 | $0.00 10-Q · filed 2020-08-04 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 derived: sum of 4 quarters · filed 2022-03-17 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 derived: sum of 4 quarters · filed 2022-03-17 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $288.00K 10-K · filed 2022-03-17 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $288.00K 10-Q · filed 2020-11-05 | $3.42M derived: sum of 4 quarters · filed 2021-03-19 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-04 | $288.00K 10-Q · filed 2020-08-04 | $3.42M derived: sum of 3 quarters · filed 2021-03-19 | $3.38M derived: sum of 4 quarters · filed 2021-03-19 | |
| 2019-03-31 | $288.00K 10-Q · filed 2020-05-07 | $3.42M derived: sum of 2 quarters · filed 2021-03-19 | $3.38M derived: sum of 3 quarters · filed 2021-03-19 | $3.09M derived: sum of 4 quarters · filed 2021-03-19 | |
| 2018-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $3.09M derived: sum of 2 quarters · filed 2021-03-19 | $2.81M derived: sum of 3 quarters · filed 2021-03-19 | $3.40M 10-K · filed 2021-03-19 | |
| 2018-09-30 | -$45.00K 10-Q · filed 2019-11-07 | -$328.00K derived: sum of 2 quarters · filed 2019-11-07 | $264.00K 10-Q · filed 2019-11-07 | -$1.08M derived: sum of 4 quarters · filed 2020-03-12 | |
| 2018-06-30 | -$283.00K 10-Q · filed 2019-08-07 | $309.00K 10-Q · filed 2019-08-07 | -$1.03M derived: sum of 3 quarters · filed 2020-03-12 | -$1.04M derived: sum of 4 quarters · filed 2020-03-12 | |
| 2018-03-31 | $592.00K 10-Q · filed 2019-05-15 | -$752.00K derived: sum of 2 quarters · filed 2020-03-12 | -$757.00K derived: sum of 3 quarters · filed 2020-03-12 | -$768.00K derived: sum of 4 quarters · filed 2020-03-12 | |
| 2017-12-31 | -$1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$1.35M derived: sum of 2 quarters · filed 2020-03-12 | -$1.36M derived: sum of 3 quarters · filed 2020-03-12 | -$1.36M 10-K · filed 2020-03-12 | $31.00K 10-K · filed 2019-03-11 |
| 2017-09-30 | -$5.00K 10-Q · filed 2018-11-09 | -$16.00K derived: sum of 2 quarters · filed 2018-11-09 | -$16.00K 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | -$11.00K 10-Q · filed 2018-08-13 | -$11.00K 10-Q · filed 2018-08-13 | |||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | -$39.00K 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |